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ABSTRACT 
Present study consists of design, synthesis of several novel substituted [3,2-f]quinazolines derivatives (3a-e) and antibacterial and 
antifungal evaluation. The structures of the synthesized derivatives were evaluated by IR, 1H-NMR, Mass and elemental analysis (C, H, 
N). Compound 3b showed significant antimicrobial spectrum.      
Keywords: substituted [3,2-f]quinazolines,  antibacterial, antifungal. 
 
 
INTRODUCTION
Bacterial threatening to society as multi-drug resistance is a big 
blow and continual drug development program is the only 
solution. Literature study explored the role of heterocyclic 
derivatives in the field of medicinal chemistry viz. 
1,3,4-thiadiazole [1-4], quinoline [5-6] and triazoles [7-10] were 
found of great significance due to their versatile biological 
activities. 3-Phenyl substituted-4-amino-5 –mercapto -1,2,4- 
triazoles were found of great interest due to  their ambient 
nucleophilic centre and generally employed as starting materials/ 
molecular manipulation for the synthesis of several interesting 
potent N-bridged heterocycles. In the current work designing and 
synthesis was focused on 1,3,4-thiadiazole, quinoline and triazole 
moieties. By adopting the conventional synthetic strategies 
several substituted 1,3,4 thiadiazoles were synthesised with the 
hope that the synthesised derivatives will better biological profile 
with the minimum amount of toxicity. 
 
RESULTS AND DISCUSSION 
Synthesis was started by the reaction of quinolin-5-ol, 
acetophenone and urea to yield compound 1, which on further 
refluxing with phosphorous oxychloride furnished compound 2. 
Condensation reaction of compound 2 and 
5,10-diphenyl-5H-[1,2,4]triazolo[4`,3`:4,5][1, 3,4] thiadiazolo 
[3,2-a] pyrido [3,2-f]quinazolines 3a-e. The synthesized 
compounds 2 and 3a-e were biologically evaluated for 
antibacterial and antifungal activity against the selected strains of 
pathogens (Table-1 & 2).  The screened derivatives 2 and 3a-e 
fungistatic activity at 1.10- 360 μmol/ml while fungicidal activity 
was achieved at 2.15-745.2 μmol/ml. Among all the tested 
derivatives, compound 3b exhibited the highest antifungal 
potential with MIC at 1.12-2.19 X 10-2 μmol/ml and MFC at 
2.18.15-4.30 μmol/ml. All the compounds showed brawny 
antibacterial activity against all bacterial species. MIC for the 
compounds 2 and 3a-e were at 0.65-74.5X 10-2 μmol/ml and MBC 
1.15-125.5X 10-2 μmol/ml. This compound showed the best 
antifungal as well as antibacterial effect among all the tested. 
Reference drugs were ampicillin (MIC 3.5–25.8 X 10-2 μmol/ml 
and MBC 8.6–51.6 X 10-2 μmol/ml) and ketoconazole (MIC 0.60–
2.38 X 10-2 μmol/ml and MFC 2.38–3.35 X 10-2 μmol/ml) for 
antibacterial and antifungal activity respectively. 
EXPERIMENTAL 
All the chemicals used for the preparation of desired derivatives, 
were obtained from Sisco Research Laboratories (SRL), Mumbai, 
India; Qualigen Fine Chemicals, Mumbai, India; E. Merck Ltd., 
New Delhi, India. The reference drugs ampicillin and 
ketoconazole were procured from Ind-Swift, Pharmaceutical, 
Panjab, India. The melting points of the compounds were 
determined in open glass capillaries with the help of thermonic 
melting points apparatus (Campbell Electronics, Mumbai, India) 
and are uncorrected. The homogeneity of all the newly 
synthesized compounds was routinely checked by TLC on silica 
gel G plates and spots were located by using iodine chamber. 
Elemental analysis was performed in Heraeus CHN rapid 
analyser. The results were found within the ±0.4% of theoretical 
values. Infrared spectra were recorded on KBr pellets on a Perkin 
Elmer system 2000 FTIR spectrometer and 1H- NMR spectra on 
Bruker DPX 200 using TMS as internal standard. 
PHARMACOLOGY 
All the newly synthesized compounds were screened for their 
antibacterial and antifungal activity against the clinically isolated 
and identified microbial strains. The antibacterial assay was 
carried out by micro dilution method [12-14] while modified 
micro dilution technique [12-11] was used for the antifungal 
activity. The minimum inhibitory, bactericidal and fungicidal 
concentrations (MICs, MBCs and MFCs) were determined by a 
serial dilution technique using 96-well microtiter plates.  
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TABLE 1: Antifungal activity of tested compounds (3a-e) (MIC & MFC in µmol/ml × 10-2) 
 
 
TABLE 2: Antibacterial activity of the tested compounds (3a-e) (MIC & MBC in µmol/ml × 10-2) 
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SCHEME-1
SYNTHESIS 
Preparation of 1-phenyl-1H-[1,3]oxazino[5,6-f]quinolin-3(2H) 
one (1) 
A mixture of quinolin-5-ol (0.01 mol), urea (0.01 mol) and 
acetophenone (0.01 mol) in ethanol was refluxed for 1 hr. The 
reaction mixture was cooled, poured into ice-water slowly with 
continuous stirring, filtered and recrystallized by methanol: Yield: 
66%; m.p.: 175 0C; Rf: 0.66. IR (KBr, cm−1): 3410 (NH), 1745 
(C=O), 1625 (C…C of aromatic ring), 1590 (C=N), 1290 
(C-O-C). 1H-NMR (CDCl3, δ/ppm): 8.60-7.42 (m, 10H, Ar-H), 
6.78 (bs, 1H, NH), 4.70 (s, 1H, CH-NH). Anal. calcd. for 
C17H12N2O2: C, 73.90; H, 4.38; N, 10.14; found C, 73.42; H,4.35; 
N,10.20. MS (m/z ): 276.09. 
Preparation of 3-chloro-1-phenyl-1H-[1,3]oxazino [5,6-f] 
quinoline (2) 
Phosphorous oxychloride (0.015 mol) added slowly to a solution 
of compound 1 (0.01 mol) in toluene. The reaction mixture was 
refluxed for 2 hrs. Excess of solvent was distilled off. The reaction 
mixture cooled. The cooled mass poured into ice-water slowly 
with continuous stirring, neutralized with aqueous 3% KOH 
solution, filtered and recrystallized by methanol: Yield: 61%; 
m.p.: 213 0C; Rf: 0.70. IR (KBr, cm−1): 1622 (C…C of aromatic 
ring), 1594 (C=N), 1288 (C-O-C). 1H-NMR (CDCl3, δ/ppm): 
8.52-7.55 (m, 10H, Ar-H), 4.75 (s, 1H, CH-N-C). Anal. calcd. for 
C17H11ClN2O: C, 69.28; H, 3.76; N, 9.50; found C, 69.31; H,3.80; 
N,9.63.MS (m/z): 294.06. 
General preparation of 5,10-diphenyl-5H- [1,2,4]triazolo 
[4`,3`:4,5][1,3,4]thiadiazolo[3,2-a]pyrido [3,2-f]quinazolines 
(3a-e) 
The solution of compound 2 (0.002 mol) in isopropanol was 
refluxed with 2-amino-5-phenyl-1,3,4-thiadiazole (0.002 mol) for 
2-3 hours. Excess of solvent was distilled off and the reaction 
mixture thus obtained was cooled, poured into ice cold water, 
washed with petroleum ether (40-60°C) and recrystallised with 
appropriate solvents to furnish the products 3a-e. Compound 3a: 
Bacterial strains Compound 2 
MIC 
MBC 
 
Compound 3a 
MIC 
MBC 
 
Compound 3b 
MIC 
MBC 
 
Compound 3c 
MIC 
MBC 
 
Compound 3d 
MIC 
MBC 
 
Compound 3e 
MIC 
MBC 
 
 
       B. cereus 
74.5 
125.2 
1.68 
 2.24 
0.65 
1.15 
2.15 
4.10 
2.00 
2.71 
2.00 
2.68 
 
S. aureus 
(ATCC) 
37.4 
49.5 
1.15 
2.19 
0.80 
1.45 
1.61 
2.15 
1.72 
2.29 
1.30 
3.36 
 
E. coli 
70.5 
122 
1.20 
1.64 
1.08 
2.15 
2.08 
4.20 
1.15 
2.29 
1.70 
 2.18 
 
P. vulgaris 
74.5 
125.5 
1.10 
 2.19 
1.24 
 2.60 
1.10 
 2.19 
1.79 
2.38 
1.64 
4.38 
Fungal strains Compound 2 
  MIC 
MFC 
 
Compound 3a 
MIC 
MFC 
 
Compound 3b 
MIC 
MFC 
 
Compound 3c 
MIC 
MFC 
 
Compound 3d 
MIC 
MFC 
 
Compound 3e 
MIC 
MFC 
 
 
A. niger 
285 
660 
1.12 
2.22 
1.10 
2.15 
1.64 
4.38 
2.10 
6.15 
2.14 
4.40 
 
A. fumigatus 
280 
665 
2.19 
4.38 
1.65 
4.20 
2.20 
4.45 
1.65 
4.32 
1.62 
4.15 
 
C. albicans 
360 
740 
2.12 
4.41 
2.19 
4.38 
2.15 
4.35 
2.25 
6.42 
2.26 
4.50 
 
C. crusie 
360 
745.2 
4.40 
6.57 
2.19 
4.38 
4.42 
6.58 
4.25 
6.24 
4.30 
6.45 
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Yield: 68%; m.p.: 240 0C; Rf: 0.76. IR (KBr, cm−1): 1620 (C…C 
of aromatic ring), 1591 (C=N), 1369(N-N), 1292 (C-O-C), 670 
(C-S-C). 1H-NMR (CDCl3, δ/ppm):  8.55-7.20 (m, 15H, Ar-H), 
4.56 (s, 1H, CH-N-C). Anal. calcd. for C25H16N6S: C, 69.43; 
H,3.73; N, 19.43; found C, 69.38; H,3.67; N,19.58. MS (m/z): 
432.12. 
 
CONCLUSION 
All the screened derivatives displayed mild to moderate 
antimicrobial profile but derivative 3b displayed significant 
antifungal and antibacterial profiles. Biological data revealed that 
the diverse substitution was well abided on the substituted 
[3,2-f]quinazolines for proper fit at the potential receptor site and 
4-chlorophenyl substitution enhanced biological activities. It 
provided broad antifungal as well as antibacterial spectrum to the 
substituted [3,2-f]quinazolines. 
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